Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor (ICI), for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM) based o
Additional File 1: Supporting data required to run the analysis, including S- and E-component signature genes from (8), number of exons in transcripts and transcript length.
